Table 3:
ORs of IDH among different classes of antihypertensive drugs in sensitivity analysis.
| Nadir 90/100 | Fall 40 | ||||
|---|---|---|---|---|---|
| Drug class | Sessions | Events | OR (95% CI)a | Events | OR (95% CI)a |
| Altered exposure definition | |||||
| ACEI/ARB | 7302 | 350 | 1.00 (0.81–1.23) | 806 | 1.02 (0.86–1.21) |
| Alpha blocker | 2287 | 46 | 0.44 (0.29–0.66) | 157 | 0.53 (0.40–0.70) |
| Beta blocker | 9348 | 512 | 0.97 (0.81–1.14) | 1050 | 1.14 (0.98–1.33) |
| DHP-CCB | 10 866 | 400 | 0.7 (0.59–0.83) | 916 | 0.84 (0.72–0.97) |
| Altered outcome definition | |||||
| ACEI/ARB | 9334 | 410 | 0.88 (0.73–1.07) | 872 | 0.82 (0.70–0.96) |
| Alpha blocker | 3347 | 90 | 0.57 (0.42–0.76) | 204 | 0.62 (0.50–0.77) |
| Beta blocker | 12 352 | 732 | 0.97 (0.84–1.12) | 1186 | 1.14 (0.96–1.34) |
| DHP-CCB | 13 236 | 469 | 0.67 (0.56–0.79) | 1024 | 0.78 (0.68–0.90) |
a
Adjusted for sex, age, diabetes mellitus, hypertension, CAD, LVEF, pre-HD SBP, dialysate flow rate, blood flow, dialysate calcium, ultrafiltration:dry weight ratio, co-medications and average ambient temperature.